CVRx, Inc. logo CVRX - CVRx, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 6
HOLD 0
SELL 1
STRONG
SELL 0
| PRICE TARGET: $10.00 DETAILS
HIGH: $10.00
LOW: $10.00
MEDIAN: $10.00
CONSENSUS: $10.00
UPSIDE: 63.67%

Stock News

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT).

May 20, 2026 12:30 PM • globenewswire.com
CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026.

May 20, 2026 12:30 PM • globenewswire.com
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.

May 14, 2026 04:00 AM • globenewswire.com
CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx Reports First Quarter 2026 Financial and Operating Results

MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarter U.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarter Active implanting centers in the U.S. grew to 257 as of March 31, 2026, as compared to 227 as of March 31, 2025 First site activated and first patient enrolled in BENEFIT-HF clinical trial "We delivered a strong start to 2026, with U.S. revenue growing 22% as the investments we made in our team and programs throughout 2025 begin to translate into results," said Kevin Hykes, President and Chief Executive Officer of CVRx.

May 11, 2026 12:05 PM • globenewswire.com
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson.

May 04, 2026 12:30 PM • globenewswire.com
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

Apr 27, 2026 12:30 PM • globenewswire.com
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026.

Apr 20, 2026 12:30 PM • globenewswire.com
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On April 7, 2025, CVRx announced first quarter re.

Mar 17, 2026 12:00 PM • businesswire.com (Hide legal announcements)
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On April 7, 2025, CVRx announced first quarter results, including revenue of only $12.

Mar 17, 2026 10:44 AM • businesswire.com (Hide legal announcements)
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CVRX, INC. (CVRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@.

Mar 17, 2026 10:41 AM • businesswire.com (Hide legal announcements)
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts.

Mar 02, 2026 03:30 AM • globenewswire.com

Price Targets